title: A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
abstract: Tumor lysis syndrome (TLS), including hyperuricemia, is a frequent serious complication in patients with hematologic malignancies. This study in Japanese patients evaluated the efficacy, safety, and pharmacokinetic profile of rasburicase in pediatric patients with hematologic malignancies. Patients aged <18 years at high risk for TLS, with newly diagnosed hematologic malignancies, were randomized to intravenous rasburicase 0.15 mg/kg/day (n = 15) or 0.20 mg/kg/day (n = 15) for 5 days. Chemotherapy was started 4-24 h after the first rasburicase dose. Response was defined as a reduction in plasma uric acid to < or = 6.5 mg/dL (patients <13 years) or < or = 7.5 mg/dL (patients > or = 13 years) by 48 h after the first administration, lasting until 24 h after the final administration. Response rates were 93.3 and 100% with rasburicase 0.15 and 0.20 mg/kg/day, respectively. Uric acid levels declined rapidly within 4 h of starting rasburicase administration in both groups. Most adverse events were related to the underlying chemotherapy regimens. Two hypersensitivity reactions, including grade 1/2 pruritus, were considered to be related to rasburicase. Rasburicase is effective and well tolerated for the management of hyperuricemia in Japanese pediatric patients at high risk of developing TLS.
authors.affiliation: Division of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan. akikuchi-tky@umin.ac.jp.|Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan. akikuchi-tky@umin.ac.jp.
authors.forename: Akira
authors.initials: A
authors.lastname: Kikuchi
authors.affiliation: Department of Hemato-oncology/Regeneration Medicine, Kanagawa Children's Medical Center, Yokohama, Japan.
authors.forename: Hisato
authors.initials: H
authors.lastname: Kigasawa
authors.affiliation: Department of Pediatrics, Aichi Medical University Hospital, Aichi, Japan.
authors.forename: Masahito
authors.initials: M
authors.lastname: Tsurusawa
authors.affiliation: Department of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan.
authors.forename: Keisei
authors.initials: K
authors.lastname: Kawa
authors.affiliation: Department of Pediatrics, Fukushima Medical University Hospital, Fukushima, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kikuta
authors.affiliation: Department of Pediatrics, Ibaraki Children's Hospital, Mito, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tsuchida
authors.affiliation: Department of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan.
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Nagatoshi
authors.affiliation: Department of Pediatrics, Niigata Cancer Center Hospital, Niigata, Japan.
authors.forename: Keiko
authors.initials: K
authors.lastname: Asami
authors.affiliation: Department of Pediatrics, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
authors.forename: Keizo
authors.initials: K
authors.lastname: Horibe
authors.affiliation: Department of Pediatrics, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Makimoto
authors.affiliation: Children's Center, Saiseikai Yokohamasi Tobu Hospital, Yokohama, Japan.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tsukimoto
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004342:Drug Hypersensitivity / Q000150:complications; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000209:etiology; D007223:Infant; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012307:Risk Factors; D016896:Treatment Outcome; D015275:Tumor Lysis Syndrome / Q000209:etiology*; D014503:Urate Oxidase / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014527:Uric Acid / Q000097:blood
chemical_list: D011994:Recombinant Proteins; C469709:rasburicase; D014527:Uric Acid; D014503:Urate Oxidase
references.citation: Pathol Oncol Res. 2007;13(1):57-62
references.pmid: 17387390
references.citation: J Clin Oncol. 2008 Jun 1;26(16):2767-78
references.pmid: 18509186
references.citation: J Clin Oncol. 2001 Feb 1;19(3):697-704
references.pmid: 11157020
references.citation: Contrib Nephrol. 2005;147:115-123
references.pmid: 15604611
references.citation: Pharmacotherapy. 2007 Jan;27(1):111-21
references.pmid: 17192165
references.citation: Semin Nephrol. 1993 May;13(3):273-80
references.pmid: 8321927
references.citation: Pediatr Blood Cancer. 2006 Apr;46(4):439-45
references.pmid: 16123985
references.citation: J Clin Oncol. 1996 Apr;14(4):1252-61
references.pmid: 8648381
references.citation: Leuk Lymphoma. 2006 Dec;47(12):2648-50
references.pmid: 17169811
references.citation: Leukemia. 2001 Oct;15(10):1505-9
references.pmid: 11587206
references.citation: Am J Med. 2004 Apr 15;116(8):546-54
references.pmid: 15063817
references.citation: Cancer Sci. 2009 Feb;100(2):357-62
references.pmid: 19076979
references.citation: BioDrugs. 2006;20(3):197-9
references.pmid: 16724869
references.citation: Expert Opin Pharmacother. 2002 Apr;3(4):433-42
references.pmid: 11934348
references.citation: J Pediatr Hematol Oncol. 2008 Apr;30(4):267-71
references.pmid: 18391694
references.citation: Cancer. 2003 Sep 1;98(5):1048-54
references.pmid: 12942574
references.citation: J Support Oncol. 2005 Mar-Apr;3(2):117-24
references.pmid: 15796443
references.citation: Curr Pharm Des. 2005;11(32):4177-85
references.pmid: 16375739
references.citation: Am J Med. 1980 Apr;68(4):486-91
references.pmid: 7369230
references.citation: Med Pediatr Oncol. 1990;18(4):283-6
references.pmid: 2355888
references.citation: Acta Haematol. 2006;115(1-2):35-8
references.pmid: 16424647
references.citation: Leukemia. 2005 Jan;19(1):34-8
references.pmid: 15510203
references.citation: Pediatrics. 1988 Dec;82(6):863-9
references.pmid: 3186376
references.citation: Blood. 2001 May 15;97(10):2998-3003
references.pmid: 11342423
references.citation: J Biol Chem. 1992 Apr 25;267(12):8565-70
references.pmid: 1339455